Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Pathway for the Development of ATR Inhibitors in Pediatric Malignancies: An ACCELERATE Multistakeholder Analysis.
Journal: JCO precision oncology
Published: January 15, 2026
Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 23, 2023
Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Journal: European journal of cancer (Oxford, England : 1990)
Published: March 06, 2023
Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy.
Journal: Cancer cell
Published: February 15, 2023
Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study.
Journal: The Lancet. Haematology
Published: September 16, 2022
Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study.
Journal: Targeted oncology
Published: April 26, 2022
Correction: MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma.
Journal: Oncotarget
Published: July 26, 2018
MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma.
Journal: Oncotarget
Published: January 19, 2018
Metabolic modulation of Ewing sarcoma cells inhibits tumor growth and stem cell properties.
Journal: Oncotarget
Published: March 21, 2017
The spliceosome is a therapeutic vulnerability in MYC-driven cancer.
Journal: Nature
Published: August 27, 2014
Last Updated: 09/26/2026